Target Price | $388.36 |
Price | $370.22 |
Potential | 4.90% |
Number of Estimates | 36 |
36 Analysts have issued a price target Visa 2026 . The average Visa target price is $388.36. This is 4.90% higher than the current stock price. The highest price target is $440.00 18.85% , the lowest is $305.00 17.62% . | |
A rating was issued by 43 analysts: 35 Analysts recommend Visa to buy, 8 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Visa stock has an average upside potential 2026 of 4.90% . Most analysts recommend the Visa stock at Purchase. |
36 Analysts have issued a sales forecast Visa 2025 . The average Visa sales estimate is $39.5b . This is 5.03% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $40.0b 6.32% , the lowest is $39.1b 3.80% .
This results in the following potential growth metrics:
2024 | $35.9b | 10.02% |
---|---|---|
2025 | $39.5b | 9.99% |
2026 | $43.7b | 10.53% |
2027 | $47.9b | 9.69% |
2028 | $52.5b | 9.54% |
21 Analysts have issued an Visa EBITDA forecast 2025. The average Visa EBITDA estimate is $27.9b . This is 6.83% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $28.9b 10.38% , the lowest is $27.3b 4.59% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $25.1b | 9.71% |
---|---|---|
2025 | $27.9b | 11.33% |
2026 | $30.8b | 10.42% |
2027 | $33.9b | 10.02% |
2028 | $37.1b | 9.22% |
2024 | 69.84% | 0.28% |
---|---|---|
2025 | 70.69% | 1.22% |
2026 | 70.62% | 0.10% |
2027 | 70.83% | 0.30% |
2028 | 70.62% | 0.30% |
24 Visa Analysts have issued a net profit forecast 2025. The average Visa net profit estimate is $23.0b . This is 16.87% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $24.2b 23.08% , the lowest is $22.3b 13.74% .
This results in the following potential growth metrics and future Net Margins:
2024 | $19.5b | 14.53% |
---|---|---|
2025 | $23.0b | 17.98% |
2026 | $27.0b | 17.59% |
2027 | $30.5b | 12.93% |
2028 | $34.0b | 11.48% |
2024 | 54.16% | 4.09% |
---|---|---|
2025 | 58.09% | 7.26% |
2026 | 61.81% | 6.40% |
2027 | 63.63% | 2.94% |
2028 | 64.75% | 1.76% |
24 Analysts have issued a Visa forecast for earnings per share. The average Visa EPS is $10.77 . This is 8.13% higher than earnings per share in the financial year 2024. The highest EPS forecast is $11.34 13.86% , the lowest is $10.48 5.22% .
This results in the following potential growth metrics and future valuations:
2024 | $9.58 | 17.69% |
---|---|---|
2025 | $10.77 | 12.42% |
2026 | $12.66 | 17.55% |
2027 | $14.30 | 12.95% |
2028 | $15.94 | 11.47% |
Current | 37.17 | 21.15% |
---|---|---|
2025 | 34.38 | 7.51% |
2026 | 29.24 | 14.95% |
2027 | 25.89 | 11.46% |
2028 | 23.22 | 10.31% |
Based on analysts' sales estimates for 2025, the Visa stock is valued at an EV/Sales of 18.35 and an P/S ratio of 18.17 .
This results in the following potential growth metrics and future valuations:
Current | 19.27 | 20.06% |
---|---|---|
2025 | 18.35 | 4.80% |
2026 | 16.60 | 9.53% |
2027 | 15.13 | 8.84% |
2028 | 13.81 | 8.71% |
Current | 19.08 | 19.50% |
---|---|---|
2025 | 18.17 | 4.79% |
2026 | 16.44 | 9.53% |
2027 | 14.98 | 8.84% |
2028 | 13.68 | 8.71% |
Analyst | Rating | Action | Date |
---|---|---|---|
Mizuho |
Neutral
➜
Outperform
|
Upgrade | Jun 05 2025 |
Truist Securities |
➜
Buy
|
Initiated | Jun 02 2025 |
UBS |
Buy
➜
Buy
|
Unchanged | May 28 2025 |
Jefferies |
Buy
➜
Buy
|
Unchanged | May 27 2025 |
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Apr 30 2025 |
Macquarie |
Outperform
➜
Outperform
|
Unchanged | Apr 30 2025 |
UBS |
Buy
➜
Buy
|
Unchanged | Apr 30 2025 |
Analyst Rating | Date |
---|---|
Upgrade
Mizuho:
Neutral
➜
Outperform
|
Jun 05 2025 |
Initiated
Truist Securities:
➜
Buy
|
Jun 02 2025 |
Unchanged
UBS:
Buy
➜
Buy
|
May 28 2025 |
Unchanged
Jefferies:
Buy
➜
Buy
|
May 27 2025 |
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Apr 30 2025 |
Unchanged
Macquarie:
Outperform
➜
Outperform
|
Apr 30 2025 |
Unchanged
UBS:
Buy
➜
Buy
|
Apr 30 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.